PAHC Stock Analysis: Buy, Sell, or Hold?
PAHC - Phibro Animal Health Corporation Class A
$33.81
-0.09 (-0.27%)
▼
5d:
-4.11%
30d:
-37.49%
90d:
-34.79%
BUY
HIGH Confidence
Analysis Updated: May 20, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When PAHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PAHC trading at deep discount. Market pricing in -12.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: PAHC trading at deep discount. Market pricing in -12.7% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$69.43
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$43.11
21.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PAHC is currently trading at $33.81, which is considered oversold relative to its 30-day fair value range of $39.22 to $58.14. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.1) compared to its historical average (15.2). Remarkably, the market is currently pricing in an annual earnings decline of 12.7% over the next few years. This pessimistic expectation contrasts with the company's recent 15.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PAHC is in a uptrend. The price is currently testing key support at $33.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.60 (+34.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PAHC is in a uptrend. The price is currently testing key support at $33.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $45.60 (+34.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$39.22 -
$58.14
Company Quality Score
55/100
(HOLD)
Options IV Signal
43th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 43th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.9% below Wall St target ($45.60)
Trading Range Analysis
30-Day Trading Range
$39.22 -
$58.14
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.30
(9.8%)
Support & Resistance Levels
Support Level
$33.05
Resistance Level
$50.87
Current Trend
Uptrend
Technical data as of
May 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.11
Wall Street Target
$45.60
(+34.9%)
Revenue Growth (YoY)
10.3%
Earnings Growth (YoY)
15.7%
Profit Margin
6.3%
Valuation Discount vs History
-12.7% cheaper
PE vs Historical
10.1 vs 15.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.7%
(market-implied from PE analysis)
1-Year Target
$30.43
(-10%)
2-Year Target
$27.39
(-19%)
3-Year Target
$24.65
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→15)
$37.05
(+10%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 8.9%)
$95.10
(+181%)
Base:
(SPY PE: 10.1, Growth: 8.9%)
$43.61
(+29%)
Bear:
(PE: 8.6, Growth: 8.9%)
$37.06
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 14.55 | Current EPS (TTM): $2.33
Bull Case
$53.52
(+58%)
Analyst growth 43.5%, PE expands to 16.0
Base Case
$48.65
(+44%)
Market implied 43.5%, PE stable at 14.6
Bear Case
$23.05
(-32%)
Severe decline -20.0%, PE contracts to 12.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.1 to 15.2
Stabilization Target:
$50.83
(+50.3%)
PE Expansion Potential:
+50.3%
Share & Embed Analysis
Last updated: May 21, 2026 12:18 AM ET
Data refreshes hourly during market hours. Next update: 1:18 AM
Data refreshes hourly during market hours. Next update: 1:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Jack Bendheim
SELL
7040 shares
2026-04-22
Jack Bendheim
SELL
7040 shares
2026-04-16
Jack Bendheim
SELL
7040 shares
2026-04-14
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 60 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 54 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced PAHC Option Strategies
Professional options setups generated by AI based on today's PAHC price and gamma walls.
